Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acquired Hemophilia A Male or female Japanese participants of >=18 years of age. 2. Participants who (or their legally authorized representatives) have provided his/her written informed consent form prior to any study-related procedures and study product administration. 3. Participants with a diagnosis of AHA based on clinical evaluation and supportive local laboratory testing as shown below Presentation with spontaneous bleeding without anatomical cause and without prior known bleeding disorder Prolonged activated partial thromboplastin time (aPTT) without explanation Abnormal aPTT cross mixing test consistent with FVIII inhibitors Confirmation of a low FVIII:C Positive FVIII inhibitor (>=0.6 BU) as measured either in the local or central laboratory 4. Participants with a severe bleeding episode which the investigator finds necessary to treat and whose severe bleeding episode meets at least 1 of the following Bleeds that pose a threat to a vital organ that could threaten life (e.g. intracranial bleed, or any site that could obstruct the airway) Bleeds that pose a threat to a vital organ where life is not threatened but the organ function could be impaired (e.g., intraspinal bleed threatening the spinal cord and/or nerve conduction; a continual bleed into the kidney or bladder that could result in an obstructive uropathy, testicular bleed, bleed in and around the eye) Bleeds requiring a blood transfusion to maintain the Hgb level at above-life or organ threatening levels (e.g. post-surgical, gastro-intestinal, retro-peritoneal, and thigh bleeds) Intramuscular bleeds where muscle viability and/or neurovascular integrity is significantly compromised or at risk of being compromised  Participants with an established reason for bleeding that is not correctable even with hemostatic therapy. 2. Participants presenting a bleeding episode that is assessed likely to resolve on its own, even if left untreated. 3. Participants with a known major sensitivity (anaphylactoid reactions) to therapeutic products of porcine or hamster origin; examples therapeutics of porcine origin (e.g. previously marketed porcine FVIII, Hyate: C) and recombinant therapeutics prepared from hamster cells (e.g. Humira, Advate, and Enbrel). 4. Participants with the use of hemophilia medication: prior to the administration of TAK-672 under one of the following conditions: (1) use of "recombinant activated factor VII (rFVI)Ia " within 3 hours prior to TAK-672 administration (2) use of " activated prothrombin complex concentrate (aPCC)" within 6 hours prior to TAK-672 administration or (3) use of " plasma-derived FX/FVIIa complex concentrate (pd-FX/FVIIa) " within 8 hours prior to TAK-672 administration. 5. Participants with an anticipated need for treatment or device during the study that may interfere with the evaluation of the safety or efficacy of TAK-672, or whose safety or efficacy may be affected by TAK-672. 6. Participants who are currently pregnant or breastfeeding, or planning to become pregnant or father a child during the study 7. Participants who have participated in another clinical study and has been exposed to an investigational product or device within 30 days prior to the study enrollment. 8. Participants who are scheduled to participate in another non-observational (interventional) clinical study involving an investigational product or device during the course of the study. 9. Participants who are unable to or unwilling to comply with the study design, protocol requirements, and/or the follow-up procedures. 10. Participants whose majority of age are under legal protection. 11. Participants who are an immediate family member, study site employee, or are in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g. spouse, parent, child, sibling) or may consent under duress. 12. Participants who are judged by the investigator as being ineligible for any other reason